Products

As the second leading cause of cancer-related deaths in the United States, and the third most common cancer worldwide, colorectal cancer is a major public health concern. There is an urgent need for a more patient-friendly, accurate and inexpensive population-based screening test for colorectal cancer. The majority of colorectal cancer and deaths could be prevented. Through regular screening, most polyps can be found and removed by colonoscopy before they develop into cancer.

Our flagship product, PolypDx™, is a urine-based test that detects both colorectal cancer and its precursors – adenomatous polyps. Current fecal-based tests have low screening compliance and do not necessarily detect precancerous polyps. Our test is an easy-to-complete, user-friendly test, designed for maximum patient acceptability. PolypDx™ provides doctors with a new tool for early screening and detection, enabling the timely removal of polyps before they progress to colorectal cancer.

Competitive Advantages of PolypDx™

Early stage detection - PolypDx™ detects adenomatous polyps, the precursor to colorectal cancer, thereby detecting individuals at risk for colorectal cancer.

High patient compliance - PolypDx™ does not require any unpleasant bowel cleansing preparation, nor unsanitary handling of stool, and does not have any health risks.

Ease of use -PolypDx™ is fast and simple – just a small urine sample is required.

Higher accuracy - Early studies suggest the potential for a higher sensitivity than fecal based tests (FOBT/FIT) for detecting adenomatous polyps.

Cost-effective and high-throughput platform - PolypDx™ is a Mass-Spectometer-based test, therefore allowing high-throughput and cost-effective population-based screening for those between 50 and 74 years.